Ventyx Biosciences, Inc. Stock Price, News & Analysis

Ventyx Biosciences (NASDAQ: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Company executives will engage in a fireside chat on Thursday, June 5, 2025, from 12:50-1:20 PM ET in New York. The presentation will be accessible via webcast on the company's website at www.ventyxbio.com, with a replay available for 90 days following the event.

Ventyx Biosciences (NASDAQ: VTYX) has expanded its Scientific Advisory Board (SAB) with seven internationally-recognized experts specializing in NLRP3 inflammasome and neurodegenerative diseases. The new appointments include Mo Lamkanfi, Luke O'Neill, Ted Dawson, Martin Pomper, Antonio Abbate, Paul Cremer, and Don Frail.

The expansion validates Ventyx's leadership in NLRP3 inflammasome chemistry and biology. The company is currently progressing two oral NLRP3 inhibitors through Phase 2 studies in Parkinson's disease, cardiometabolic disease, and recurrent pericarditis. Notably, topline data from the Phase 2 study of VTX3232, their CNS-penetrant NLRP3 inhibitor for Parkinson's disease, is expected in Q2 2025.

Ventyx Biosciences (VTYX) reported its Q4 and full year 2024 financial results, highlighting multiple upcoming Phase 2 data readouts in 2025. The company maintains a strong financial position with $252.9 million in cash and equivalents, expected to fund operations into H2 2026.

Key pipeline updates include:

• VTX2735 Phase 2 trial in recurrent pericarditis results expected in H2 2025
• VTX3232 Phase 2 trial in obesity and cardiometabolic risk factors data expected in H2 2025
• VTX3232 biomarker study in early Parkinson's disease completion expected in Q2 2025

Financial highlights for 2024:

• R&D expenses decreased to $117.0M from $175.8M in 2023
• G&A expenses slightly decreased to $31.4M from $32.2M in 2023
• Net loss improved to $135.1M compared to $193.0M in 2023

Ventyx Biosciences (VTYX) announced Phase 2 trial results for VTX958, its TYK2 inhibitor for Crohn's disease. While the trial did not meet its primary endpoint of change in Crohn's Disease Activity Index (CDAI), likely due to high placebo response, it demonstrated significant endoscopic improvements. The study showed dose-dependent endoscopic response rates of 24.3% for 225mg and 32.4% for 300mg doses, compared to 5.7% for placebo at Week 12.

The trial involved 109 subjects randomized across placebo and two VTX958 dosage groups (225mg and 300mg BID) for a 12-week induction period, followed by a 40-week maintenance phase. Notable results included significant reductions in SES-CD scores for both dosage groups compared to placebo, and improved clinical-biomarker response rates (43.2% for 300mg vs 14.3% for placebo). The company is analyzing full 52-week data to inform future development strategy and partnership opportunities.

Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company specializing in innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

The virtual event is scheduled for Wednesday, February 12, 2025, from 2:40-3:10 PM ET. The company will provide a presentation, which will be accessible via webcast through the Investors and News section of Ventyx's website at www.ventyxbio.com. A replay of the presentation will remain available on the website for ninety days following the event.

Ventyx Biosciences (NASDAQ: VTYX) has outlined its 2025 pipeline strategy, focusing on its NLRP3 inhibitor portfolio. The company has initiated three significant Phase 2 trials: VTX3232 for obesity and cardiometabolic risk factors (topline data expected H2 2025), VTX2735 for recurrent pericarditis (starting January, topline data H2 2025), and VTX3232 for early Parkinson's disease (topline data H1 2025).

The company reported $252.9M in cash and equivalents as of December 31, 2024, expected to fund operations into H2 2026. Regarding their IBD portfolio, they are exploring partnership opportunities for tamuzimod in ulcerative colitis, while analyzing Phase 2 data for VTX958 in Crohn's disease to inform future development strategy.

Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for inflammatory diseases, has announced its participation in three major investor conferences. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18, the Jefferies London Healthcare Conference on November 20, and the Piper Sandler Healthcare Conference in New York on December 4. Webcasts of all presentations will be available on the company's website for thirty days following each event.

Ventyx Biosciences (VTYX) reported Q3 2024 financial results and pipeline updates. The company maintains a strong cash position of $274.8 million, expected to fund operations into H2 2026. Net loss decreased to $35.2 million from $54.0 million in Q3 2023, while R&D expenses reduced to $30.6 million from $49.8 million.

Key pipeline developments include planned Phase 2 trials for VTX2735 in recurrent pericarditis and VTX3232 in obesity, both expected to initiate by year-end. Topline results from VTX3232's Phase 2a trial in early Parkinson's disease are anticipated in H1 2025. The company seeks partnership for tamuzimod's Phase 3 trial in ulcerative colitis.